Each step. Every patient. Exactly what you need.
Schedule a meeting with us
The 2025 ASTRO Annual Meeting is happening soon, and we would love to connect with you while in San Francisco. We also invite you to visit our new booth 3407 to learn how we are bringing together genomic, germline, and somatic testing products to support you across the prostate cancer care continuum.
You will also learn how the Prolaris® Prostate Cancer Prognostic Test is the leader in personalized androgen deprivation therapy (ADT) decisions and the only test to provide absolute risk-benefit of adding ADT post radiation therapy.1
We look forward to seeing you at our booth to learn more about Myriad Oncology’s comprehensive suite of services.
Tumor Testing in NCCN Favorable and Unfavorable Intermediate-Risk Prostate Cancer Informs Treatment Intensity: Data from an Open Access Research Registry
Presenter: Dr. Christopher Lee, Radiation Oncologist, Cancer Care NorthwestDate: Tuesday, September 30Time: 12:45PM-2PM PDT
Request more information about how Myriad’s Oncology solutions can benefit you/your patients.
By submitting your personal information, you agree to be contacted with newsletters, marketing or promotional materials, and other information that may be of interest to you. You may opt-out of receiving communications from us by following the unsubscribe link or the instructions provided in the communication we send. For further information on our privacy practices and commitment to protecting your privacy, please visit our Privacy Notice.
Contact Information
Reference: